Novocure (NSDQ:NVCR) shares rose slightly this morning after the cancer-treatment developer reported its preliminary fourth quarter and full-year revenues.
The St. Helier, N.J.-based company said it expects to land $53.7 million in net revenue for the fourth quarter of 2017, up 77% from the same period last year. For the full year, Novocure anticipates it will post sales of $177 million, representing 114% growth year-over-year.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure revenues climb in Q4, FY17 prelims appeared first on MassDevice.